Moreover, they have demonstrated through in silico analysis of TCGA-GBM-RNASeq that GPM-GBM cases with an activated TLR4 pathway may benefit from metformin treatment, but the simultaneous upregulation of CXCL8/IL8 may require a combination therapy with an IL8 inhibitor. The gene discussed is TLR4; the disease is glioblastoma.